Company: RNAC
Filing Date: 2025-10-30
Form Type: 8-K
Source: 0001140361-25-039793
Chunk: 0

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-10-30
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.  

In connection with her recent appointment as Executive Chair of another publicly-traded company and the additional responsibilities and time
commitment related thereto, on October 29, 2025, Carrie S. Cox, a member of the Board of Directors (the “ Board”) of Cartesian Therapeutics, Inc. (the “ Company”), notified the Company of her resignation from the Board, effective immediately. Prior to
her resignation, Ms. Cox served as Chairman of the Board, as Chairman of the Board’s Compensation Committee and as a member of the Board’s Audit Committee. In connection with her resignation from the Board, Ms. Cox will cease service as Chairman of
the Board and on such committees. Ms. Cox’s resignation was not the result of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Ms. Cox has served as Chairman of the Board since 2019, providing exemplary service and many important contributions during her tenure. The Company
thanks Ms. Cox for her advice and leadership as Chairman of the Board and wishes Ms. Cox well as she focuses on her other commitments.

In connection with Ms. Cox’s resignation from the Board, on October 29, 2025, the Board appointed Carsten Brunn, Ph. D., as Chairman of the Board,
appointed Patrick Zenner, M. B. A., as Lead Independent Director of the Board, and appointed Kemal Malik, M. B. B. S., as Chairman of the Board’s Compensation Committee. Dr. Brunn will not receive any additional compensation for service in his role as
Chairman of the Board. Mr. Zenner will be provided compensation for his service as Lead Independent Director of the Board and Dr. Malik will be provided compensation for his service as Chairman of the Board’s Compensation Committee in accordance with
the Company’s Non-Employee Director Compensation Program.

  Item 5.03      Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.